NDA 022212 · Sandoz
Durezol
Difluprednate · Ophthalmic
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jun 23, 2008
Approved uses
3
Original approval plus efficacy supplements
Registered trials
23
13 Phase 3, 0 recruiting
FAERS reports
3,862
1,778 serious, 126 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 18, 2026.
Difluprednate ophthalmic emulsion is a corticosteroid indicated for: • The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) • The treatment of endogenous anterior uveitis. ( 1.2 ) 1.1 Ocular Surgery Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery. 1.2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is indicated for the treatment of endogenous anterior uveitis.
Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2013 Supplement 11 · Efficacy · priority review LabelPediatric Written RequestPediatric Amendment 1
- Jun 13, 2012 Supplement 3 · Efficacy OrphanLetterLabel
- Jun 23, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLetterLabel
1 products under this application
- DUREZOL · DIFLUPREDNATE 0.05% · EMULSION, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Difluprednate" as an intervention, any sponsor and status, largest first.
- Evaluation of Anti-Inflammatory Treatment in Dry Eye PatientsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01276223 · 722 participants · Start Feb 2011 · Primary completion Jan 2012
Drug: Difluprednate 0.05% ophthalmic emulsion · For: Dry Eye Disease
Sites: Fort Worth, Texas
- Steroids and Cross-linking for Ulcer TreatmentPivotal-lookingCompleted
Thomas M. LietmanAcademic, hospital or other
NCT04097730 · 280 participants · Start Sep 24, 2020 · Primary completion May 18, 2024
Drug: Moxifloxacin Ophthalmic; Difluprednate Ophthalmic and 1 more · For: Keratitis Bacterial
Sites: San Francisco, California; Miami, Florida; Madurai, India
- Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.Pivotal-lookingCompleted
Laboratorios PoenIndustry
NCT04631315 · 255 participants · Start Mar 24, 2019 · Primary completion May 24, 2020
Drug: Difluprednate Ophthalmic Emulsion 0.05%; Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution · For: Cataract
Sites: Ciudad Autonoma de Buenos Aire, Argentina
- Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)Pivotal-lookingCompleted
Sirion Therapeutics, Inc.Industry
NCT00429923 · 219 participants
Drug: Difluprednate; Difluprednate and 1 more · For: Inflammation
Sites: Washington, Missouri
- Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)Pivotal-lookingCompleted
Sirion Therapeutics, Inc.Industry
NCT00430092 · 219 participants
Drug: Difluprednate; Difluprednate and 1 more · For: Inflammation
Sites: Washington, Missouri
- Study of Difluprednate Ophthalmic Emulsion in Postoperative InflammationPivotal-lookingCompleted
Sirion Therapeutics, Inc.Industry
NCT00406341 · 200 participants · Start Apr 2004
Drug: Difluprednate Ophthalmic Emulsion · For: Inflammation
- Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After PhacoemulsificationPivotal-lookingCompleted
Laboratorios Sophia S.A de C.V.Industry
NCT03693989 · 178 participants · Start Oct 4, 2018 · Primary completion Aug 7, 2019
Drug: Difluprednate 0.05%; Prednefrin · For: Cataract
Sites: Guadalajara, Mexico; Monterrey, Mexico; Mexico City, Mexico · 5 sites in all
- Study of Difluprednate Ophthalmic Emulsion in the Treatment of UveitisPivotal-lookingCompleted
Sirion Therapeutics, Inc.Industry
NCT00406887 · 140 participants · Start Aug 2002
Drug: Difluprednate Ophthalmic Emulsion · For: Anterior Uveitis; Panuveitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- intraocular pressure increased530
- drug ineffective251
- eye pain243
- vision blurred193
- off label use178
- eye irritation175
- cataract158
- visual impairment155
- fatigue135
- headache126
- therapy partial responder105
- diarrhoea101
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 29 |
| 2012 | 52 |
| 2013 | 68 |
| 2014 | 80 |
| 2015 | 169 |
| 2016 | 533 |
| 2017 | 578 |
| 2018 | 355 |
| 2019 | 402 |
| 2020 | 338 |
| 2021 | 243 |
| 2022 | 236 |
| 2023 | 256 |
| 2024 | 191 |
| 2025 | 177 |
| 2026 | 124 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Durezol (Difluprednate)
2024 spending
$805K
Beneficiaries
1,541
2,990 claims
Per beneficiary
$522
$42.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $629,269 |
| 2024 | $804,791 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis.
KhalafAllah MT, Basiony A, Salama A · BMJ Open 2019 · Meta-Analysis, Systematic Review
- Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.
Foster CS, Davanzo R, Flynn TE, et al. · J Ocul Pharmacol Ther 2010 · Clinical Trial, Phase III, Comparative Study
- Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies.
Sheppard JD, Foster CS, Toyos MM, et al. · Ocul Immunol Inflamm 2019 · Clinical Trial, Phase III, Multicenter Study
- Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Korenfeld MS, Silverstein SM, Cooke DL, et al. · J Cataract Refract Surg 2009 · Clinical Trial, Phase III, Multicenter Study
- Fill levels, cost comparisons, and expulsion force requirements of commonly used topical ophthalmic steroids.
Gill MS, Murphy DA, Dvorak JD, et al. · J Cataract Refract Surg 2022 · Clinical Trial
- Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.
Sheppard JD, Toyos MM, Kempen JH, et al. · Invest Ophthalmol Vis Sci 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.